Special issue “The advance of solid tumor research in China”: Real‐world clinical outcomes of alectinib for advanced nonsmall‐cell lung cancer patients with ALK fusion in China
Sign Up to like & getrecommendations! Published in 2022 at "International Journal of Cancer"
DOI: 10.1002/ijc.34123
Abstract: Global phase 3 trials have demonstrated the priority of several next‐generation anaplastic lymphoma kinase‐tyrosine kinase inhibitors (ALK‐TKIs). However, clinical studies are conducted with specific populations that differ from the real world. The study aimed to… read more here.
Keywords: clinical outcomes; world; outcomes alectinib; china ... See more keywords